Concepedia
Statistics
Publications
25
Citations
4.2K
H-Index
19
Active since
2011
Affiliations
Pfizer (United States)(Current)
Massachusetts General Hospital
Dana-Farber Cancer Institute
Peter MacCallum Cancer Centre
University of Colorado Denver
Yiyun Tang is an author at Pfizer (United States) specializing in medicine, oncology, and pharmacology.
Publications per year
2011–2025
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations
Medicine, Oncology, Pharmacology +15
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon et al. · The Lancet Oncology · 2011 · 900 citations
Medicine, Oncology, Pharmacology +14
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
Benjamin Solomon, Dong‐Wan Kim, Yi‐Long Wu et al. · Journal of Clinical Oncology · 2018 · 412 citations
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Stephen J. Freedland, Murilo Luz, Ugo De Giorgi et al. · New England Journal of Medicine · 2023 · 291 citations
Pharmacy, Pharmacology, Pharmacotherapy +15
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
S.-H.I. Ou, Pasi A. Jänne, Cynthia Huang Bartlett et al. · Annals of Oncology · 2014 · 220 citations · Full text
1–5 of 25